Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis.
Jennie H BestAmanda M KongDavid M SmithIbrahim AbbassMargaret MichalskaPublished in: ClinicoEconomics and outcomes research : CEOR (2019)
In patients with GCA, OGC-related AEs increased with increasing cumulative OGC dose, resulting in increased healthcare costs. These results highlight the need for efficacious therapies that reduce the exposure to and potential risks associated with OGCs.